Acasti Pharma Inc.
NASDAQ:ACST
3.37 (USD) • At close October 25, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0.196 | 0 | 0 | 0 | 0 | 0.028 | 0.216 | 0.45 | 0.707 | 0.127 | 0.029 | 0 |
| Cost of Revenue
| 0 | 0.011 | 52.155 | 15.589 | 0.076 | 2.32 | 2.333 | 0 | 0 | 0.06 | 0.188 | 0.262 | 0.397 | 0.005 | 0 | 0 |
| Gross Profit
| 0 | -0.011 | -52.155 | -15.589 | 0.12 | -2.32 | -2.333 | 0 | 0 | -0.032 | 0.028 | 0.188 | 0.31 | 0.005 | 0.029 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0.612 | 0 | 0 | 0 | 0 | -1.162 | 0.131 | 0.417 | 0.439 | 0.042 | 1 | 0 |
| Reseach & Development Expenses
| 9.511 | 4.628 | 9.972 | 5.559 | 4.173 | 15.974 | 28.734 | 12.133 | 0 | 5.453 | 5.212 | 5.446 | 2.939 | 3.159 | 1.573 | 1.121 |
| General & Administrative Expenses
| 7.168 | 6.432 | 8.076 | 9.263 | 5.513 | 8.16 | 4.238 | 3.118 | 0 | 1.607 | 4.722 | 4.448 | 4.189 | 0 | 0.858 | 0 |
| Selling & Marketing Expenses
| 0 | 0.341 | 0.136 | -0.518 | 1.142 | -2.665 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 7.168 | 6.18 | 6.953 | 9.781 | 6.655 | 8.464 | 4.238 | 3.118 | 0 | 1.607 | 4.722 | 4.448 | 4.189 | 3.514 | 0.858 | 0.409 |
| Other Expenses
| 0 | 0 | 0.063 | 0 | 5.711 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.147 | 0.011 |
| Operating Expenses
| 16.679 | 11.301 | 18.247 | 15.34 | 10.836 | 19.108 | 32.973 | 15.252 | 0 | 7.06 | 9.935 | 9.894 | 7.128 | 6.556 | 2.466 | 1.538 |
| Operating Income
| 0 | -11.312 | -24.608 | -15.589 | -16.419 | -24.438 | -33.714 | -15.252 | 0 | -7.093 | -9.906 | -9.706 | -6.818 | -6.551 | -3.189 | -1.539 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -83.77 | 0 | 0 | 0 | 0 | -255.254 | -45.8 | -21.561 | -9.638 | -51.534 | -109.814 | 0 |
| Total Other Income Expenses Net
| 0 | -3.318 | -45.631 | 4.711 | -3.259 | -1.513 | -4.906 | -1.4 | 0 | 2.431 | 8.517 | -0.73 | 0.087 | 0.012 | 0.113 | 0.011 |
| Income Before Tax
| -12.767 | -14.685 | -51.971 | -10.467 | -19.678 | -25.513 | -38.62 | -16.652 | 0 | -6.317 | -1.323 | -10.436 | -6.732 | -6.539 | 0 | -1.527 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -100.398 | 0 | 0 | 0 | 0 | -227.328 | -6.117 | -23.183 | -9.517 | -51.439 | 0 | 0 |
| Income Tax Expense
| 0 | -1.777 | -9.542 | -0.648 | -0.127 | 0.247 | 5.241 | 0.291 | 0 | -2.379 | -8.517 | 0 | -0.042 | 0.022 | -0.012 | -0.03 |
| Net Income
| -12.767 | -12.853 | -42.429 | -9.819 | -19.678 | -25.76 | -43.862 | -16.943 | 0 | -4.661 | -1.323 | -10.436 | -6.732 | -6.539 | -3.076 | -1.508 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -100.398 | 0 | 0 | 0 | 0 | -167.734 | -6.117 | -23.183 | -9.517 | -51.439 | -105.923 | 0 |
| EPS
| -0.79 | -1.35 | -5.71 | -1.6 | -7.96 | -8.38 | -6.46 | -7.75 | 0 | -20.99 | -5.98 | -59.37 | -44.42 | -46.68 | -22.71 | -33.5 |
| EPS Diluted
| -0.79 | -1.35 | -5.71 | -1.6 | -7.96 | -8.48 | -6.46 | -7.75 | 0 | -20.99 | -5.98 | -59.37 | -44.42 | -46.68 | -22.71 | -33.5 |
| EBITDA
| 0 | -14.619 | 15.847 | -19.989 | -9.792 | -21.828 | -30.989 | -14.008 | 0 | -5.271 | -7.97 | -8.841 | -6.08 | -5.858 | -2.389 | -1.53 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -49.959 | 0 | 0 | 0 | 0 | -189.686 | -36.849 | -19.64 | -8.595 | -46.084 | -82.266 | 0 |